The investigators propose the first prospective, double blind, randomized controlled trial of
treatment for pulmonary arterial hypertension (PAH) related to underlying portal
hypertension. Specifically the investigators will evaluate the potential efficacy and safety
of sildenafil (Revatio) in a 16 week blinded, multicentre study.